Initiating digoxin in AF patients associated with early hazard of sudden death - PACE-CME

Initiating digoxin in AF patients associated with early hazard of sudden death

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

PCI-registry-based trial shows that IFR is non-inferior to FFR, with reduced discomfort and stenting
PCI-registry-based trial shows that IFR is non-inferior to FFR, with reduced discomfort and stenting
ACC.17
PCI-registry-based trial shows that IFR is non-inferior to FFR, with reduced discomfort and stenting
The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials
The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials
ACC.17
The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials
- Prof. Stephen J. Nicholls
Identification of patients who will benefit is important after FOURIER
Identification of patients who will benefit is important after FOURIER
ACC.17
Identification of patients who will benefit is important after FOURIER
- Prof. Ulf Landmesser
The implications of PCSK9 outcome trials for GPs
The implications of PCSK9 outcome trials for GPs
ACC.17
The implications of PCSK9 outcome trials for GPs
- Prof. Richard Hobbs, MD